CRISPR Therapeutics and Vertex Pharmaceuticals have noted that the medicine currently has an addressable market of roughly 60 ...

A new meta-analysis reveals that breast reduction surgery is linked to improvements in sexual desire, arousal, and satisfaction. Researchers suggest that alleviating physical pain and reducing ...

Merck & Co. and Moderna always knew they would be making headlines in Madrid this week—just not in the way it panned out. | Merck & Co. and Moderna always knew they would be making headlines in Madrid ...

Roche ( RHHBY) announced new late-breaking data from the ongoing Phase III IMAgINATION study showing that its investigational therapy sefaxersen delivered a statistically significant and clinically ...

On October 23, 2026, Climb Bio, Inc. and Beijing Mabworks Biotech Co., Ltd. announced additional Phase 1 data in healthy volunteers for CLYM116/MIL116, an anti-APRIL monoclonal antibody in development ...

Climb Bio, Inc. (Nasdaq: CLYM, "Climb Bio”) and Beijing Mabworks Biotech Co., Ltd. ("Mabworks”), today announced additional Phase 1 data in healthy volunteers for CLYM116/MIL116, an anti-APRIL ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing ...

Real-world analysis showed serum phosphate reductions following XPHOZAH initiation across all phosphate binder groups ...

Moderna is rated a Hold, citing valuation concerns, lack of definitive long-term efficacy data, and significant execution and ...

Merck and Moderna's intismeran with Keytruda cut melanoma recurrence or death risk by 42% in the Phase III INTerpath-001 trial. Read the full details now.

DENALI Part 1b study (GOG-3066) as of a May 22, 2026 data cutoff, including the first overall survival analysis for azenosertib, at the European Society for Medical Oncology (ESMO) Congress 2026 in ...

By Bhanvi Satija and Marleen Kaesebier LONDON/ZURICH, Oct 23 (Reuters) - Swiss drugmaker Novartis' oral multiple sclerosis ...